Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector.


We developed a novel vaccine platform based on a paramyxoviral, genome replication-deficient Sendai virus vector that can express heterologous genes inserted into the genome. To validate the novel approach in vivo, we generated a combined vaccine candidate against human respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (PIV3). The… (More)
DOI: 10.1016/j.vaccine.2013.06.053


5 Figures and Tables

Slides referencing similar topics